Potential prognostic factors for molecular relapse: univariate analysis
| Variable . | Cumulative incidence of relapse by 48 mo (95% CI) . | Overall P value . |
|---|---|---|
| Age | 0.154 | |
| >60 y (n = 28) | 54.78% (38.85-77.24) | |
| ≤60 y (n = 32) | 36.72% (22.49-59.95) | |
| Sex | 0.577 | |
| Male (n = 22) | 36.36% (20.92-63.2) | |
| Female (n = 38) | 49.66% (35.45-69.55) | |
| Sokal score | 0.623 | |
| Low (n = 32) | 42.71% (27.88-65.3) | |
| Intermediate + high (n = 25) | 49.1% (33.07-74.74) | |
| Prior IFN-α | 0.637 | |
| Yes (n = 17) | 41.76% (23.67-73.7) | |
| No (n = 43) | 45.94% (32.65-64.64) | |
| TKI treatment duration | 0.643 | |
| >76 mo (n = 30) | 47.11% (32.13-69.08) | |
| ≤76 mo (n = 30) | 42.29% (27.10-66) | |
| 2G-TKI treatment duration | 0.772 | |
| >39 mo (n = 29) | 44.83% (29.94-67.13) | |
| ≤39 mo (n = 31) | 44.31% (29.22-67.19) | |
| uMR4.5 duration | 0.597 | |
| >29 mo (n = 29) | 37.93% (23.81-60.42) | |
| ≤29 mo (n = 31) | 50.52% (35.13-72.66) | |
| 2G-TKI type | 0.331 | |
| Dasatinib (n = 30) | 50.83% (35.52-72.76) | |
| Nilotinib (n = 30) | 38.62% (29.99-62.15) | |
| Prior intolerance or resistance to TKI | 0.00233 | |
| Yes (n = 13) | 35.51% (23.73-53.15) | |
| No (n = 47) | 76.92% (57.11-100) |
| Variable . | Cumulative incidence of relapse by 48 mo (95% CI) . | Overall P value . |
|---|---|---|
| Age | 0.154 | |
| >60 y (n = 28) | 54.78% (38.85-77.24) | |
| ≤60 y (n = 32) | 36.72% (22.49-59.95) | |
| Sex | 0.577 | |
| Male (n = 22) | 36.36% (20.92-63.2) | |
| Female (n = 38) | 49.66% (35.45-69.55) | |
| Sokal score | 0.623 | |
| Low (n = 32) | 42.71% (27.88-65.3) | |
| Intermediate + high (n = 25) | 49.1% (33.07-74.74) | |
| Prior IFN-α | 0.637 | |
| Yes (n = 17) | 41.76% (23.67-73.7) | |
| No (n = 43) | 45.94% (32.65-64.64) | |
| TKI treatment duration | 0.643 | |
| >76 mo (n = 30) | 47.11% (32.13-69.08) | |
| ≤76 mo (n = 30) | 42.29% (27.10-66) | |
| 2G-TKI treatment duration | 0.772 | |
| >39 mo (n = 29) | 44.83% (29.94-67.13) | |
| ≤39 mo (n = 31) | 44.31% (29.22-67.19) | |
| uMR4.5 duration | 0.597 | |
| >29 mo (n = 29) | 37.93% (23.81-60.42) | |
| ≤29 mo (n = 31) | 50.52% (35.13-72.66) | |
| 2G-TKI type | 0.331 | |
| Dasatinib (n = 30) | 50.83% (35.52-72.76) | |
| Nilotinib (n = 30) | 38.62% (29.99-62.15) | |
| Prior intolerance or resistance to TKI | 0.00233 | |
| Yes (n = 13) | 35.51% (23.73-53.15) | |
| No (n = 47) | 76.92% (57.11-100) |
Quantitative variables were categorized into 2 groups with cutoffs set at median. P < .05 was considered statistically significant.